| scholarly article | Q13442814 |
| P356 | DOI | 10.1211/0022357056118 |
| P698 | PubMed publication ID | 15969931 |
| P50 | author | Tsutomu Nakamura | Q57023886 |
| P2093 | author name string | Toshiro Niwa | |
| Katsuhiko Okumura | |||
| Toshiyuki Sakaeda | |||
| Kohshi Nishiguchi | |||
| Noboru Okamura | |||
| Mikio Kakumoto | |||
| Koichi Iwaki | |||
| Jiang-shu Jin | |||
| Mika Nishikawa | |||
| P2860 | cites work | In vitro activation of 7-benzyloxyresorufin O-debenzylation and nifedipine oxidation in human liver microsomes | Q44534145 |
| Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study | Q44832013 | ||
| In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin | Q44941953 | ||
| Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics | Q46055776 | ||
| Interaction between fluconazole and midazolam in intensive care patients. | Q51458169 | ||
| Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. | Q51553057 | ||
| Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. | Q51562990 | ||
| Echinocandin antifungal drugs | Q29398696 | ||
| Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data | Q32061089 | ||
| Transporter-Enzyme Interactions: Implications for Predicting Drug-Drug Interactions from In Vitro Data | Q33193683 | ||
| Effects of the antifungal agents on oxidative drug metabolism: clinical relevance | Q33858325 | ||
| The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors | Q34065800 | ||
| Active secretion and enterocytic drug metabolism barriers to drug absorption | Q34190323 | ||
| Antifungal agents: mechanisms of action | Q34208354 | ||
| Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes | Q34359090 | ||
| Genetic polymorphisms of the human MDR1 drug transporter | Q34931160 | ||
| Role of P-glycoprotein in pharmacokinetics: clinical implications | Q35029495 | ||
| Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. | Q35048738 | ||
| Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs | Q35164664 | ||
| Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance | Q35642041 | ||
| Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism | Q36093518 | ||
| Natural history of opportunistic disease in an HIV-infected urban clinical cohort | Q39420529 | ||
| Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes | Q39652863 | ||
| Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. | Q40449494 | ||
| Rapid assessment of P-glycoprotein inhibition and induction in vitro | Q40639122 | ||
| Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression | Q40716924 | ||
| Simvastatin and lovastatin, but not pravastatin, interact with MDR1. | Q40743825 | ||
| HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. | Q42060921 | ||
| Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice | Q42464794 | ||
| Interaction of digoxin with antihypertensive drugs via MDR1. | Q42518658 | ||
| Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors | Q44217892 | ||
| P433 | issue | 6 | |
| P921 | main subject | multiple drug resistance | Q643839 |
| P304 | page(s) | 759-764 | |
| P577 | publication date | 2005-06-01 | |
| P1433 | published in | Journal of Pharmacy and Pharmacology | Q10532762 |
| P1476 | title | Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs | |
| P478 | volume | 57 |
| Q36290698 | A review of clinical experience with newer antifungals in children |
| Q48238550 | Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. |
| Q53544619 | Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism. |
| Q38015710 | Azole interactions with multidrug therapy in pediatric oncology |
| Q28273738 | Comparison of echinocandin antifungals |
| Q59285092 | Design and Antimicrobial Evaluation of 1-Methylimidazole Derivatives as New Antifungal and Antibacterial Agents |
| Q33390377 | Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib |
| Q43108275 | Effects of multiple oral dosing of itraconazole on the pharmacokinetics of cyclosporine in cats |
| Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
| Q38825266 | Evaluation of the effect of fluconazole on the pharmacokinetics of cyclosporin A in healthy dogs after a single dose and at steady-state |
| Q40164902 | Haloperidol is an inhibitor but not substrate for MDR1/P-glycoprotein |
| Q37904672 | Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. |
| Q42038812 | Homology modeling and docking studies on oxidosqualene cyclases associated with primary and secondary metabolism of Centella asiatica |
| Q38462784 | Impact of special patient populations on the pharmacokinetics of echinocandins. |
| Q34058209 | In vitro and in vivo evidence for amphotericin B as a P-glycoprotein substrate on the blood-brain barrier |
| Q34211108 | In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats |
| Q40746038 | Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP. |
| Q64131246 | Interacciones farmacológicas en el paciente crítico. ¿Un factor relevante para usar micafungina? |
| Q90645513 | Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics |
| Q35026516 | Micafungin in the treatment of invasive candidiasis and invasive aspergillosis |
| Q36895679 | Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice |
| Q37288766 | Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections |
| Q38053482 | Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections |
| Q37535957 | Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients |
| Q34197425 | Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme |
| Q37377752 | Recent approaches to antifungal therapy for invasive mycoses. |
| Q42111914 | Role of plasma proteins in pharmacokinetics of micafungin, an antifungal antibiotic, in analbuminemic rats |
| Q37827883 | Safety of micafungin in infants: insights into optimal dosing |
| Q42868963 | Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women |
| Q36828156 | The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety |
| Q36626518 | The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications |
| Q37331953 | The enzymatic basis of drug-drug interactions with systemic triazole antifungals. |
| Q46224687 | Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation |
| Q52780226 | Vincristine toxicity with co-administration of fluconazole during induction therapy for pediatric acute lymphoblastic leukemia. |
| Q46000239 | [Micafungin for therapy of invasive candidiasis in solid organ transplant recipients]. |
Search more.